Recent 8-K filings for CV

• May 14, 2026, 4:08 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs

  Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.

• March 26, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  CapsoVision reports 15% revenue growth in FY2025; completes $14M private placement

  Q4 2025 revenue $3.9M (+13% YoY); full year $13.6M (+15% YoY) driven by higher capsule sales.

• March 20, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 2.02item 3.02item 7.01item 8.01item 9.01 ◈ Material Agreements ×2

  CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M

  Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.

• March 13, 2026, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 9.01 ◈ Material Agreements

  CapsoVision amends Canon development deal; total fee increased by $1.0M

  Total fee under CMOS image sensor development agreement with Canon raised by $1.0M due to increased features.

• December 29, 2025, 6:59 PM ET regulatory materiality 0.55 positive item 8.01item 9.01

  CapsoVision submits 510(k) to FDA for AI-assisted reading module for CapsoCam Plus

  Submitted 510(k) to FDA for proprietary AI-assisted module for CapsoCam Plus capsule endoscopy system.

• November 13, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule

  Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.

• November 10, 2025, 6:59 PM ET regulatory materiality 0.60 neutral item 8.01item 9.01

  CapsoVision files FDA Breakthrough Device application for pancreatic cancer screening capsule

  Submitted BDD application to FDA on Nov 6, 2025 for CapsoCam UGI capsule to detect early-stage pancreatic ductal adenocarcinoma.

• November 3, 2025, 6:59 PM ET leadership materiality 0.50 neutral item 5.02item 7.01item 9.01

  CapsoVision appoints David Garcia as SVP of Finance and principal financial officer

  Effective Nov 3, 2025; Garcia previously VP of FP&A at Matterport, led IPO and M&A.

• September 26, 2025, 7:59 PM ET leadership materiality 0.20 neutral item 5.02

  CapsoVision Senior Director of Clinical Affairs to retire; Keri Jorgenson promoted

  Rebecca Petersen to retire as Senior Director of Clinical Affairs effective Oct 15, 2025.

• September 3, 2025, 7:59 PM ET leadership materiality 0.65 negative item 5.02

  CFO Kevin Lundquist steps down; CapsoVision begins successor search

  Kevin Lundquist resigned as CFO effective Aug 27, 2025; company started search for replacement.

• August 14, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M

  Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.

• July 18, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  CapsoVision signs $4.1M CMOS sensor development agreement with Canon; overallotment yields $0.6M

  Development agreement with Canon for CMOS image sensor samples; total fee ~$4.1M, $1M cash upfront, remainder via unit price add-on in future purchase agreement.

• July 3, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  CapsoVision closes IPO of 5.5M shares at $5.00; gross proceeds $27.5M

  Completed IPO of 5,500,000 shares at $5.00/share, raising $27.5M in gross proceeds.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event earnings

3 positive 1 negative 9 neutral

source · CV on sec.gov